Etravirine indications and usage: Difference between revisions
Ahmed Zaghw (talk | contribs) Created page with "__NOTOC__ {{Etravirine}} {{CMG}}; {{AE}} {{AZ}} ==References== {{Reflist}} {{FDA}} Category:Antibiotics Category:Wikinfect" |
Gerald Chi (talk | contribs) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Indications and Usage== | |||
INTELENCE®1, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced patients ages 6 years and older, who have evidence of viral replication and [[HIV-1]] strains resistant to a non-nucleoside reverse transcriptase inhibitor ([[NNRTI]]) and other antiretroviral agents. | |||
The indication for adult use is based on Week 48 analyses from 2 randomized, double-blind, placebo-controlled trials of INTELENCE®. Both studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults. The indication for pediatric use is based on 24-week analyses of a single-arm, Phase 2 trial in antiretroviral treatment-experienced pediatric subjects 6 years to less than 18 years of age [seeUse in Specific Populations (8.4)]. | |||
In treatment-experienced adult and pediatric patients, the following points should be considered when initiating therapy with INTELENCE®: | |||
Treatment history and resistance testing should guide the use of INTELENCE® due to concerns for potential cross-resistance. | |||
In patients who have experienced virologic failure on an NNRTI-containing regimen, do not use INTELENCE® in combination with only N[t]RTIs [seeClinical Studies (14)]. | |||
The use of other active antiretroviral agents with INTELENCE® is associated with an increased likelihood of treatment response. | |||
The safety and efficacy of INTELENCE® have not been established in pediatric patients less than 6 years of age or in treatment-naïve adult or pediatric patients.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = INTELENCE (ETRAVIRINE) TABLET [JANSSEN PRODUCTS LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a9cbc29-9f15-4b24-8d86-206b82887f3d | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 17:01, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Indications and Usage
INTELENCE®1, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced patients ages 6 years and older, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents.
The indication for adult use is based on Week 48 analyses from 2 randomized, double-blind, placebo-controlled trials of INTELENCE®. Both studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults. The indication for pediatric use is based on 24-week analyses of a single-arm, Phase 2 trial in antiretroviral treatment-experienced pediatric subjects 6 years to less than 18 years of age [seeUse in Specific Populations (8.4)].
In treatment-experienced adult and pediatric patients, the following points should be considered when initiating therapy with INTELENCE®:
Treatment history and resistance testing should guide the use of INTELENCE® due to concerns for potential cross-resistance.
In patients who have experienced virologic failure on an NNRTI-containing regimen, do not use INTELENCE® in combination with only N[t]RTIs [seeClinical Studies (14)]. The use of other active antiretroviral agents with INTELENCE® is associated with an increased likelihood of treatment response. The safety and efficacy of INTELENCE® have not been established in pediatric patients less than 6 years of age or in treatment-naïve adult or pediatric patients.[1]
References
Adapted from the FDA Package Insert.